Mironid Presents Translational Data at European Renal Association Congress

Glasgow, Scotland, May 28, 2024 – Mironid, a leading biopharmaceutical company, has recently showcased encouraging preclinical results of its innovative LoAc® compound at the European Renal Association (ERA) Congress held on May 25, 2024, in Stockholm, Sweden. The focus of the presentation was on the potential of the LoAc® compound to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD), a prevalent hereditary kidney disorder affecting over 12 million individuals globally.

ADPKD is marked by the formation of numerous fluid-filled cysts in the kidneys, leading to organ enlargement, functional decline, and various complications. Current treatment options are limited, making the development of effective therapies critical.

Dr. Adele Rowley, Mironid’s Chief Scientific Officer, delivered a presentation entitled 'Targeting cAMP in ADPKD by small molecule activation of long form PDE4 enzymes'. This presentation detailed how the activation of long form PDE4 enzymes and subsequent increase in cyclic AMP (cAMP) hydrolysis by the LoAc® compound can directly address the elevated kidney cAMP levels that drive cyst formation in ADPKD.

Mironid’s LoAc® compounds are pioneering small molecules designed to reduce cAMP levels, thereby inhibiting cyst growth in both in vitro and in vivo settings. The translational data presented by Dr. Rowley showed significant reductions in cAMP levels in ADPKD models following treatment with the LoAc® compound. These findings suggest that LoAc® compounds could potentially slow the progression of renal disease, reducing the need for dialysis and offering a new therapeutic avenue for ADPKD patients.

The company is now in the process of selecting a development candidate from its LoAc® programme to advance into clinical trials for ADPKD treatment. This step is crucial for translating the promising preclinical results into viable clinical outcomes.

Mironid's commitment to addressing ADPKD stems from the severe impact of the disease, characterized by the uncontrolled growth of kidney cysts. By targeting the underlying mechanisms driving the disease, Mironid aims to provide a much-needed treatment option for patients.

Mironid's efforts are supported by a team of experienced industry professionals and a robust advisory network. The company has garnered substantial backing from prominent investors, including Roche Venture Fund, Epidarex Capital, Sofinnova Partners, and BioGeneration Ventures. Additionally, the University of Strathclyde, the Scottish Investment Bank, and the European Investment Fund (EIF) are among the notable supporters of Mironid.

In conclusion, the presentation of preclinical data at the ERA Congress marks a significant milestone for Mironid in its mission to develop effective treatments for ADPKD. The positive results from the LoAc® compound in reducing cAMP levels and inhibiting cyst growth provide a promising outlook for future clinical applications. As the company moves forward with selecting a development candidate, there is hope for a new, effective treatment for those suffering from this debilitating hereditary kidney disease.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!